Diez-Campelo M, Yucel A, Goyal R, Parikh R, Dhuliawala S, Jimenez M, Sluga-O'Callaghan M, Hughes C, Tang D, Germing U. Systemic therapy utilization and hematologic outcomes in lower-risk myelodysplastic syndromes (LR-MDS): findings from a real-world medical record review study in the US, UK, and Europe (EU). Poster presented at the 2022 European Hematology Association Hybrid Congress; June 10, 2022. Vienna, Austria.
Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473
Davis KL, Cote I, Kaye JA, Gao H, Perez Ronco J, Seifeldin R, Mendelson E. Real-world assessment of clinical outcomes in lower-risk myelofibrosis patients receiving treatment with ruxolitinib. Poster presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition; December 6, 2014. San Francisco, CA. [abstract] Blood. 2014 Dec 6; 124(21):1857. doi: 10.1182/blood.V124.21.1857.1857
Price GL, Davis KL, Karve SJ, Pohl G, Walgren RA. Survival patterns in elderly patients with myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):428. doi: 10.1182/blood.V120.21.428.428
Ahern TP, Pedersen L, Svaerke C, Rothman KJ, Sorensen HT, Lash TL. The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable. Am J Epidemiol. 2011 Dec 1;174(12):1382-90.
Wolowacz S, Roskell N, Plumb J, Clemens A, Robinson P, Dolan G, Brenkel I. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. [abstract] Value Health. 2009 May; 12(3):A151.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150 MG for the prevention of venous thromboembolism in patients aged over 75 years undergoing total hip or knee arthroplasty. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 14, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.